Tag: BioNTech

October 26, 2023 Off

Medigene ends 3Q in line with financial expectations

By Dino Mustafić

Medigene  has reported its financial performance in the third quarter of 2023 was in line with the Executive Management Board’s expectations, as the revenues in the third quarter 2023 amounted to EUR 1.6 million compared to EUR 1.4 million in the previous year period (9-month period 2023: EUR 4.6 million), primarily from the partnership with BioNTech.

June 29, 2023 Off

BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC

By Dino Mustafić

BioNTech and US based OncoC4 today announced that the first patient with non-small cell lung cancer (NSCLC) has been treated in a pivotal Phase 3 trial evaluating the companies’ next-generation anti-CTLA-4 antibody candidate BNT316/ONC-392 (gotistobart). The trial is part of BioNTech’s strategy to initiate multiple pivotal trials in 2023 and 2024, the companies said in a press release Thursday.